CD4 and urinary bladder carcinoma: Together with the predictive value of a cytotoxic CD4+ T cell signature for anti-PD-L1 response in bladder cancer (Oh et al., 2020), this suggests a role for PD-1 blockade in enhancing the activity of these cells.